Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLSD Clearside Biomedical	$0.38 -7.8%	$0.72	$0.29 ▼ $1.65	$32.37M	2.09	13.04 million shs	814,430 shs
LSB LakeShore Biopharma	$0.73 -11.0%	$1.03	$0.70 ▼ $8.60	N/A	0.56	892,295 shs	61,718 shs
MRSN Mersana Therapeutics	$6.60 -3.6%	$8.50	$6.37 ▼ $70.75	$34.15M	0.83	130,548 shs	110,562 shs
SNYR Synergy CHC	$3.36 -2.9%	$2.83	$0.36 ▼ $10.00	$31.81M	N/A	54,733 shs	29,375 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLSD Clearside Biomedical	-7.80%	-22.75%	-52.34%	-55.84%	-66.31%
LSB LakeShore Biopharma	-10.98%	-36.52%	-27.36%	-38.66%	-83.76%
MRSN Mersana Therapeutics	-3.65%	-18.04%	-5.61%	-33.62%	-86.80%
SNYR Synergy CHC	-2.89%	-11.35%	+3.70%	+57.75%	+3,260.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLSD Clearside Biomedical	3.0171 of 5 stars	4.1	5.0	0.0	2.8	0.0	0.0
LSB LakeShore Biopharma	0.4206 of 5 stars	0.0	3.0	0.0	0.8	0.8	0.6
MRSN Mersana Therapeutics	3.8708 of 5 stars	3.4	4.0	4.1	0.6	2.5	0.0
SNYR Synergy CHC	3.8798 of 5 stars	3.8	0.0	0.0	3.3	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLSD Clearside Biomedical	2.17	Hold	$4.20	993.47% Upside
LSB LakeShore Biopharma	0.00	N/A	N/A	N/A
MRSN Mersana Therapeutics	2.83	Moderate Buy	$130.00	1,869.70% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	197.62% Upside

Current Analyst Ratings Breakdown

Latest LSB, CLSD, SNYR, and MRSN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$225.00 ➝ $250.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLSD Clearside Biomedical	$1.66M	17.98	N/A	N/A	($0.51) per share	-0.75
LSB LakeShore Biopharma	$85.67M	N/A	N/A	N/A	$8.86 per share	N/A
MRSN Mersana Therapeutics	$40.50M	0.81	N/A	N/A	($1.92) per share	-3.44
SNYR Synergy CHC	$34.83M	0.89	$0.26 per share	13.01	($1.91) per share	-1.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLSD Clearside Biomedical	-$34.35M	-$0.41	N/A	N/A	N/A	-818.57%	N/A	-114.23%	8/11/2025 (Estimated)
LSB LakeShore Biopharma	-$61.09M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$14.75	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
SNYR Synergy CHC	$2.12M	N/A	0.00	5.69	N/A	N/A	-8.48%	12.75%	N/A

Latest LSB, CLSD, SNYR, and MRSN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MRSN Mersana Therapeutics	-$0.18	N/A	N/A	N/A	$6.06 million	N/A
8/11/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	N/A	N/A	N/A	$0.50 million	N/A
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$5.25	-$4.75	+$0.50	-$0.19	$6.05 million	$2.75 million
5/15/2025	Q1 2025	SNYR Synergy CHC	$0.07	$0.10	+$0.03	$0.10	$9.03 million	$8.17 million
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
LSB LakeShore Biopharma	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLSD Clearside Biomedical	N/A	3.19	3.19
LSB LakeShore Biopharma	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	1.83	1.83
SNYR Synergy CHC	N/A	1.91	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLSD Clearside Biomedical	18.75%
LSB LakeShore Biopharma	52.64%
MRSN Mersana Therapeutics	93.92%
SNYR Synergy CHC	N/A

Insider Ownership

Company	Insider Ownership
CLSD Clearside Biomedical	6.20%
LSB LakeShore Biopharma	N/A
MRSN Mersana Therapeutics	13.00%
SNYR Synergy CHC	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLSD Clearside Biomedical	30	77.71 million	72.89 million	Optionable
LSB LakeShore Biopharma	773	N/A	N/A	N/A
MRSN Mersana Therapeutics	150	4.99 million	4.34 million	Optionable
SNYR Synergy CHC	40	9.19 million	3.99 million	N/A

LSB, CLSD, SNYR, and MRSN Headlines

Recent News About These Companies

Insider Buying: Synergy CHC Corp. (NASDAQ:SNYR) CEO Purchases 3,750 Shares of Stock

August 1 at 6:41 AM | insidertrades.com

Synergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call Information

July 31 at 12:47 AM | manilatimes.netM

Synergy CHC Corp. Stock (SNYR) Opinions on Retail Distribution Expansion

July 31 at 1:12 PM | quiverquant.comQ

Reviewing Synergy CHC (NASDAQ:SNYR) & Swatch Group (OTCMKTS:SWGAY)

July 29, 2025 | americanbankingnews.com

Synergy CHC Expands Retail Presence in North America

June 30, 2025 | tipranks.com

Synergy CHC Corp. (SNYR) Stock Price Today - WSJ

June 24, 2025 | wsj.com

Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue Streams

June 18, 2025 | finance.yahoo.com

Synergy CHC Corp. Expands International Licensing Deal with Gravity Pharma to Include Turkey, Securing $2 Million in Revenue

June 18, 2025 | quiverquant.comQ

Here is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)

June 18, 2025 | finance.yahoo.com

Here is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)

June 16, 2025 | insidermonkey.com

Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 9,400 Shares

June 12, 2025 | insidertrades.com

New to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink’s Global Expansion

June 11, 2025 | freep.comF

New to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink's Global Expansion

June 10, 2025 | guardonline.comG

Synergy CHC Corp. Appoints Damian Marano as Vice President of Beverage to Accelerate Functional Beverage Expansion

June 10, 2025 | quiverquant.comQ

Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion

June 10, 2025 | globenewswire.com

Synergy CHC secures $20 million loan for growth and debt repayment

June 5, 2025 | investing.com

Synergy CHC Secures $20 Million Loan Agreement

June 4, 2025 | msn.com

Synergy CHC Announces New $20 Million Long-Term Credit Facility

June 4, 2025 | globenewswire.com

SNYR Synergy CHC Corp.

May 30, 2025 | seekingalpha.com

Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

May 29, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSB, CLSD, SNYR, and MRSN Company Descriptions

Clearside Biomedical NASDAQ:CLSD

$0.38 -0.03 (-7.80%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.39 +0.01 (+2.58%)

As of 08/1/2025 07:59 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

LakeShore Biopharma NASDAQ:LSB

$0.73 -0.09 (-10.98%)

Closing price 08/1/2025 03:52 PM Eastern

Extended Trading

$0.72 -0.02 (-2.05%)

As of 08/1/2025 07:31 PM Eastern

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

Mersana Therapeutics NASDAQ:MRSN

$6.60 -0.25 (-3.65%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.60 0.00 (0.00%)

As of 08/1/2025 07:43 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Synergy CHC NASDAQ:SNYR

$3.36 -0.10 (-2.89%)

As of 08/1/2025 04:00 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time